Groupe d'étude en oncologie du Québec

// Research Protocols

Clinical Trials

1 to 10 de 283 clinical trials

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 |

Trial Title Trial ID ClinicalTrials.gov ID	Cancer Site	Institution

A Phase II Study of Ribavirin in Refractory of Relapsed Acute Myelocytic Leukemia M4 and M5 Subtypes Borden-001 NCT00559091	Acute Myeloid Leukemia	Hôpital Maisonneuve-Rosemont

A phase III multi-center, open-label, randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP). CAMN107a2303 NCT00471497	Acute Myeloid Leukemia	Centre hospitalier de l'Université de Montréal (CHUM) Hôpital Notre-Dame

Phase II study of temozolomide in previously untreated acute myeloid leukemia (AML) patients unsuitable for standard induction therapy exhibiting low MGMT expression. P05052 NCT00687323	Acute Myeloid Leukemia	Hôpital Maisonneuve-Rosemont

A phase III randomized, double-lind, controlled study comparing clofarabine and cytarabine vs cytarabine alone in adult patients > 60 years old with acute myelogenous leukemia (AML) who have relapsed or are refractory after receiving up to two prior induction regimens CLO34100405 NCT00317642	Acute Myeloid Leukemia	Hôpital Maisonneuve-Rosemont

A phase III study of the addition of gemtuzumab ozogamicin (Mylotarg) induction therapy vs standard induction with daunomycin and cytosine arabinoside followed by consolidation and subsequent randomization to post-consolidation therapy with gemtuzumab ozogamicin (Mylotarg) or no additional therapy for patients under age 56 with previously untreated denovo acute myeloid leukemia (AML). NCIC CTG ALC.1 NCT00085709	Acute Myeloid Leukemia	Hôpital Maisonneuve-Rosemont

A phase III study of the addition of gemtuzumab ozogamicin (mylotarg) during induction therapy versus standard induction with daunomycin and cytosine arabinoside followed by consolidation and subsequent randomization to post-consolidation therapy with gemtuzumab ozogamicin (mylotarg) or no additional therapy for patients under age 56 with previously untreated de novo acute myeloid leukemia (AML). NCIC CTG ALC.1 NCT00085709	Acute Myeloid Leukemia	Hôpital Général Juif Sir Mortimer B.Davis (Étude du programme d'oncologie de McGill)

A phase III study of the addition of gemtuzumab ozogamicin (mylotarg) during induction therapy versus standard induction with daunomycin and cytosine arabinoside followed by consolidation and subsequent randomization to post-consolidation therapy with gemtuzumab ozogamicin (mylotarg) or no additional therapy for patients under age 56 with previously untreated de novo acute myeloid leukemia (AML). NCIC CTG ALC.1 NCT00085709	Acute Myeloid Leukemia	Centre universitaire de santé McGill (Étude du programme d'oncologie de McGill)

Randomized phase 3 trial of decitabine versus patient’s choice with physicians’s advice of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. McG 0528 NCT00260832	Acute Myeloid Leukemia	Hôpital Général Juif Sir Mortimer B.Davis (Étude du programme d'oncologie de McGill)

Randomized phase 3 trial of decitabine versus patient’s choice with physicians’s advice of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. McG 0528 NCT00260832	Acute Myeloid Leukemia	Centre universitaire de santé McGill (Étude du programme d'oncologie de McGill)

A Phase II study of Ribavarin in refractory or relapsed acute myelocytic leukemia M4 and M5 Subtypes. CR0602KB NCT00559091	Acute Myeloid Leukemia	Hôpital Général Juif Sir Mortimer B.Davis

1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 |